US Edition
Pα+ Psychedelic Bulletin #206: Q2’25 Psychedelic Lobbying; Tabernanthalog’s Neuroplasticity Pathway; UK Moves to Ease Schedule I Research Restrictions - Psychedelic Alpha
Summary by psychedelicalpha.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Pα+ Psychedelic Bulletin #206: Q2’25 Psychedelic Lobbying; Tabernanthalog’s Neuroplasticity Pathway; UK Moves to Ease Schedule I Research Restrictions - Psychedelic Alpha
Each quarter, we provide a look at federal lobbying disclosures by psychedelic drug developers and nonprofits. That data is a lagging indicator, especially as filings are not required immediately at the end of each quarter. Here’s a review of Q2 2025 activity… Psychedelic drug developers’ spend on federal lobbying in Q2’25 looked very similar to that seen in the first quarter… Source
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
